Theravance Reviews

3.4
5 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
Theravance President, CEO, and Director Rick E. Winningham
Rick E. Winningham
3 Ratings
  • Sceintist

    • Comp & Benefits
    • Work/Life Balance
    • Culture & Values
    • Career Opportunities
    Former Employee - Anonymous Employee
    Former Employee - Anonymous Employee

    I worked at Theravance

    Recommends
    Approves of CEO
    Recommends
    Approves of CEO

    Pros

    Great place to work; competitive; good work environment

    Cons

    Top heavy; few opportunities for growth

Theravance Interviews

Updated Feb 24, 2015

Interview Experience

Interview Experience

25%
25%
50%

Getting an Interview

Getting an Interview

50%
50%

Interview Difficulty

3.2
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Research Associate I Interview

    Accepted Offer
    Positive Experience
    Average Interview
    Accepted Offer
    Positive Experience
    Average Interview

    Application

    I applied through an employee referral. The process took 4+ weeksinterviewed at Theravance (South San Francisco, CA) in December 2014.

    Interview

    First had a phone interview with the hiring manager. Then invited to a whole-day on-site interview with a half-a-hour presentation. Met with ~10 people, including the director and VP from the department in 1:1 or 2:1 settings. Last talked to HR. Questions were pretty straight forward. Hiring process was efficient.

    Interview Questions

Theravance Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.theravance.com
Headquarters South San Francisco, CA
Size 150 to 499 Employees
Founded 1996
Type Company - Public (THRX)
Industry Biotech & Pharmaceuticals
Revenue $1 to $5 million (USD) per year

Theravance figures there's no sense in re-inventing the wheel. The biotechnology firm takes aim at already proven biological targets, taking advantage of previous years of research to create more effective, next-generation treatments. Its development programs focus on respiratory disease, bacterial infections, and gastrointestinal and neurological conditions. Its sole marketed product, VIBATIV (an injectable antibiotic approved to treat skin infections and hospital-acquired pneumonia) was successfully developed and commercialized with partner Astellas. In an exclusive... More

Work at Theravance? Share Your Experiences

Theravance

 
Click to Rate
or